AMPH — Amphastar Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1297184 ·
Last close
$29.10
Market Cap
$1.24B
52W High
$31.00
52W Low
$16.65
ADV30
455,900
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 207,608,000 | 99,629,000 | 50,773,000 | 37,763,000 | 1,711,724,000 | 204,588,000 | 897,170,000 |
| Jun 2026 | 183,903,000 | 93,470,000 | 39,729,000 | 30,348,000 | 1,743,766,000 | 223,614,000 | 975,609,000 |
| Mar 2026 | 171,171,000 | 70,322,000 | 13,630,000 | 6,420,000 | 1,648,162,000 | 170,939,000 | 874,771,000 |
| Dec 2025 | 183,105,000 | 85,670,000 | 35,606,000 | 24,429,000 | 1,629,299,000 | 170,177,000 | 840,494,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$184,610,000
Investing CF
$-52,051,000
Financing CF
$-96,462,000
CapEx
$-31,718,000
Dividends Paid
—
Buybacks
$-100,071,000
EPS Diluted TTM
$1.69
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$703,649,000
Inventory
$179,907,000
Receivables
$147,485,000
ST Investments
$66,509,000
EBIT TTM
$128,149,000
Pretax Income TTM
$102,023,000
Interest Exp TTM
$26,126,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$745,787,008
EBITDA
$221,422,000
Free Cash Flow
$14,027,000
Enterprise Value
$1,676,214,912
Total Cash
$230,634,000
Total Debt
$691,689,024
Shares Out
42,648,323
Trailing EPS
$2.18
Book Value
$19.10
ROE
12.4%
ROA
6.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 719,887,000 | 140,403,000 | 98,094,000 | 1,629,299,000 | 840,494,000 | 788,805,000 | 156,115,000 |
| Dec 2024 | 731,967,000 | 205,419,000 | 159,519,000 | 1,577,470,000 | 845,172,000 | 732,298,000 | 213,386,000 |
| Dec 2023 | 644,395,000 | 196,987,000 | 137,545,000 | 1,512,912,000 | 873,491,000 | 639,421,000 | 183,503,000 |
| Dec 2022 | 498,987,000 | 107,497,000 | 91,386,000 | 741,987,000 | 213,329,000 | 528,658,000 | 89,181,000 |
TTM Snapshot
Revenues TTM
$730,019,000
NetIncome TTM
$78,547,000
OpCashFlow TTM
—
Assets (Latest)
$1,743,766,000
Forward EPS
$3.17
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $29.71 · call volume: 15 · put volume: 8
Expected Move to 2027-03-19:
±$6.77
(22.79%) —
implied range
$22.94 –
$36.48
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.24B | $27.92 | — |
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| SLN | Silence Therapeutics plc | $1.23B | $19.80 | — |
| GHRS | GH Research PLC | $1.25B | $18.27 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.23B | $13.14 | — |
News headlines (Yahoo Finance, 1h cache)
Is Amphastar Pharmaceuticals (AMPH) Fully Priced After Strong Q3 Earnings And Q4 Guidance?
2026-11-13 04:35 · Yahoo
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
2026-11-11 11:00 · Yahoo
AMPH Q3 2026 deep dive: pipeline progress and manufacturing challenges shape outlook
2026-11-10 09:25 · Yahoo
Should Earnings Beat Require Action From Amphastar Pharmaceuticals (AMPH) Investors?
2026-11-07 16:12 · Yahoo
Amphastar (AMPH) Q3 2026 Earnings Call Transcript
2026-11-06 16:28 · Yahoo
Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue of $207. ...
2026-11-06 07:20 · Yahoo
Amphastar Pharmaceuticals Q3 Earnings Call Highlights
2026-11-06 00:14 · Yahoo
Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars
2026-11-05 22:16 · Yahoo
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
2026-11-05 21:45 · Yahoo
Amphastar: Q3 Earnings Snapshot
2026-11-05 21:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.